Latest Insider Transactions at Provectus Biopharmaceuticals, Inc. (PVCT)
This section provides a real-time view of insider transactions for Provectus Biopharmaceuticals, Inc. (PVCT). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of PROVECTUS BIOPHARMACEUTICALS, INC. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of PROVECTUS BIOPHARMACEUTICALS, INC.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Aug 12
2024
|
Jeffrey Allen Morris > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
264,314
+5.84%
|
$528,628
$2.86 P/Share
|
|
May 08
2023
|
Jeffrey Allen Morris > 10% Shareholder |
BUY
Conversion of derivative security
|
Direct |
188,757
+4.51%
|
$377,514
$2.86 P/Share
|
|
Nov 10
2020
|
Bruce Horowitz COO |
BUY
Grant, award, or other acquisition
|
Direct |
800,000
+26.43%
|
-
|
|
Nov 10
2020
|
John Lacy Iii Director |
BUY
Grant, award, or other acquisition
|
Direct |
100,000
+33.33%
|
-
|
|
Nov 10
2020
|
Heather Raines CFO |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+3.96%
|
-
|